Pembrolizumab (Keytruda®) for the first line treatment of adults with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/07/2021|
|Rapid review completed||05/08/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.|